The Medical Letter on Drugs and Therapeutics
Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ceftazidime/avibactam (Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options. Ceftolozane/tazobactam (Zerbaxa – Cubist), another cephalosporin/beta-lactamase inhibitor combination, was approved in 2014.1

SPECTRUM — Ceftazidime is a third-generation cephalosporin with activity against enteric gram-negative bacilli, but minimal to no activity against anaerobic or gram-positive pathogens. Avibactam is a non-beta-lactam beta-lactamase inhibitor that inhibits the activity of enyzmes in Ambler classes A and C, and some in class D.

The addition of avibactam improves ceftazidime's activity against Pseudomonas aeruginosa and many extended-spectrum beta-lactamase (ESBL)-producing gram-negative pathogens. Ceftazidime/avibactam is the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ceftazidime Avibactam (Avycaz) - A New Intravenous Antibiotic
Article code: 1469c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian